Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply
- 7 September 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (9) , 873
Abstract
In Reply In response to our study on tapering of csDMARDs in patients with RA in remission,1 Dr Baker and colleagues discuss the potential for successful tapering, and even drug-free remission, in RA. They highlight that our study results can be interpreted differently than the main conclusion of the article, which was also discussed in the Editorial by Curtis et al.2Keywords
This publication has 6 references indexed in Scilit:
- Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in RemissionJAMA, 2021
- Treatment Strategies for Patients With Immune-Mediated Inflammatory DiseasesJAMA, 2021
- The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patientsSeminars in Arthritis and Rheumatism, 2020
- Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort studyJournal of Autoimmunity, 2019
- Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directionsAnnals of the Rheumatic Diseases, 2016
- It's like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimesRheumatology, 2013